X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the acquisition, Essential Pharma has acquired rights to Reminyl (galantamine hydrobromide), a cholinesterase inhibitor, oral capsules in the EEA, Thailand, South Korea and all other current markets for that product, excluding UK and Ireland, Japan and Latin America.
Lead Product(s): Galantamine Hydrobromide
Therapeutic Area: Neurology Product Name: Reminyl
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Johnson & Johnson Innovative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 17, 2024
Details:
Through the acquisition, Essential Pharma will leverage Renaissance clinical-stage immunotherapy product Hu14.18 (Hu14.18K322A) for the treatment of high-risk neuroblastoma.
Lead Product(s): Hu14.18K322A
Therapeutic Area: Oncology Product Name: Hu14.18
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Renaissance Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 09, 2024
Details:
Under the acquisition, Essential Pharma has acquired the rights to Colobreathe (colistimethate sodium), indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa (PsA) in patients with cystic fibrosis, across European markets.
Lead Product(s): Colistimethate Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Colobreathe
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Teva Pharmaceutical Industries
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 08, 2024
Details:
Iopidine (apraclonidine hydrochloride), is an alpha2-adrenergic agonist, a sympathomimetic used in glaucoma therapy. It is used as a short-term adjunctive therapy in open-angle glaucoma who are on maximally tolerated medical therapy requiring additional IOP reduction.
Lead Product(s): Apraclonidine Hydrochloride
Therapeutic Area: Ophthalmology Product Name: Iopidine
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2023
Details:
IOPIDINE (apraclonidine hydrochloride), is a short-term adjunctive therapy for chronic glaucoma to prevent or control intraocular pressure including after selective laser therapy, a form of laser eye surgery now recommended as the initial treatment for open angle glaucoma.
Lead Product(s): Apraclonidine Hydrochloride
Therapeutic Area: Ophthalmology Product Name: Iopidine
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
HALDOL® (haloperidol decanoate) is a first-generation ‘typical’ antipsychotic for the treatment of schizophrenia and some other psychiatric conditions such as schizoaffective disorder and moderate to severe manic episodes associated with bipolar I disorder.
Lead Product(s): Haloperidol Decanoate
Therapeutic Area: Psychiatry/Psychology Product Name: Haldol
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Johnson & Johnson Innovative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 07, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
